Casanova J, Peel J, Donadieu J, Neehus A, Puel A, Bastard P
    
    
    Nat Immunol. 2024; 25(5):743-754.
  
  
    PMID: 38698239
    
    
          DOI: 10.1038/s41590-024-01815-y.
      
 
                                  
  
    Bouayad A
    
    
    Am J Transl Res. 2024; 16(2):374-386.
  
  
    PMID: 38463591
    
          PMC: 10918145.
    
      
 
                                  
  
    Cheng A, Holland S
    
    
    Nat Rev Immunol. 2023; 24(3):161-177.
  
  
    PMID: 37726402
    
    
          DOI: 10.1038/s41577-023-00933-2.
      
 
                                  
  
    Shaw E, Matzinger P
    
    
    Front Immunol. 2023; 14:1046300.
  
  
    PMID: 36742299
    
          PMC: 9889632.
    
          DOI: 10.3389/fimmu.2023.1046300.
      
 
                                  
  
    Stertz S, Hale B
    
    
    Trends Microbiol. 2021; 29(11):973-982.
  
  
    PMID: 33757684
    
          PMC: 7980109.
    
          DOI: 10.1016/j.tim.2021.03.001.
      
 
                              
              
                              
                                      
  Minireview: Insights into anti-interferon-γ autoantibodies.
  
    Chawansuntati K, Rattanathammethee K, Wipasa J
    
    
    Exp Biol Med (Maywood). 2021; 246(7):790-795.
  
  
    PMID: 33430618
    
          PMC: 8719035.
    
          DOI: 10.1177/1535370220981579.
      
 
                                          
                                                          
  The first US domestic report of disseminated Mycobacterium avium complex and anti-interferon-γ autoantibodies.
  
    OConnell E, Rosen L, LaRue R, Fabre V, Melia M, Auwaerter P
    
    
    J Clin Immunol. 2014; 34(8):928-32.
  
  
    PMID: 25149293
    
          PMC: 9278557.
    
          DOI: 10.1007/s10875-014-0073-9.
      
 
                                          
                                                          
  Autoantibodies against granulocyte-macrophage colony stimulating factor and interleukin-3 are rare in patients with Felty's syndrome.
  
    Hellmich B, Ciaglo A, Schatz H, Coakley G
    
    
    Ann Rheum Dis. 2004; 63(7):862-6.
  
  
    PMID: 15194585
    
          PMC: 1755075.
    
          DOI: 10.1136/ard.2003.011056.
      
 
                                          
                                                          
  Detection of autoantibodies to cytokines.
  
    Bendtzen K, Hansen M, Ross C, Svenson M
    
    
    Mol Biotechnol. 2000; 14(3):251-61.
  
  
    PMID: 10890016
    
    
          DOI: 10.1385/MB:14:3:251.
      
 
                                          
                                                          
  Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease.
  
    Meager A, Wadhwa M, Bird C, Dilger P, Thorpe R, Newsom-Davis J
    
    
    Immunology. 1999; 97(3):526-32.
  
  
    PMID: 10447777
    
          PMC: 2326850.
    
          DOI: 10.1046/j.1365-2567.1999.00806.x.
      
 
                                          
                                                          
  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.
  
    Lucey D, Clerici M, Shearer G
    
    
    Clin Microbiol Rev. 1996; 9(4):532-62.
  
  
    PMID: 8894351
    
          PMC: 172909.
    
          DOI: 10.1128/CMR.9.4.532.
      
 
                                          
                                                          
  A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities.
  
    Babcook J, Leslie K, Olsen O, Salmon R, Schrader J
    
    
    Proc Natl Acad Sci U S A. 1996; 93(15):7843-8.
  
  
    PMID: 8755564
    
          PMC: 38836.
    
          DOI: 10.1073/pnas.93.15.7843.
      
 
                                          
                                                          
  Binding of cytokines to pharmaceutically prepared human immunoglobulin.
  
    Svenson M, Hansen M, Bendtzen K
    
    
    J Clin Invest. 1993; 92(5):2533-9.
  
  
    PMID: 8227366
    
          PMC: 288439.
    
          DOI: 10.1172/JCI116862.
      
 
                                          
                                                          
  Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta.
  
    Fierlbeck G, Schreiner T, Schaber B, Walser A, Rassner G
    
    
    Cancer Immunol Immunother. 1994; 39(4):263-8.
  
  
    PMID: 7954528
    
          PMC: 11038129.
    
          DOI: 10.1007/BF01525990.
      
 
                                          
                                                          
  High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
  
    Ross C, Svenson M, Hansen M, Vejlsgaard G, Bendtzen K
    
    
    J Clin Invest. 1995; 95(5):1974-8.
  
  
    PMID: 7738163
    
          PMC: 295769.
    
          DOI: 10.1172/JCI117881.
      
 
                                          
                                                          
  Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome.
  
    Zeidner N, Myles M, Dreitz M, Mullins J, Hoover E
    
    
    Antimicrob Agents Chemother. 1990; 34(9):1749-56.
  
  
    PMID: 2178336
    
          PMC: 171917.
    
          DOI: 10.1128/AAC.34.9.1749.
      
 
                                          
                                                          
  Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis.
  
    Ikeda Y, Toda G, Hashimoto N, Umeda N, Miyake K, Yamanaka M
    
    
    Clin Exp Immunol. 1991; 85(1):80-4.
  
  
    PMID: 1906385
    
          PMC: 1535714.
    
          DOI: 10.1111/j.1365-2249.1991.tb05686.x.
      
 
                                          
                                                          
  Anti-IL-1 alpha autoantibodies in patients with rheumatic diseases and in healthy subjects.
  
    Suzuki H, Ayabe T, Kamimura J, Kashiwagi H
    
    
    Clin Exp Immunol. 1991; 85(3):407-12.
  
  
    PMID: 1893621
    
          PMC: 1535622.
    
          DOI: 10.1111/j.1365-2249.1991.tb05740.x.
      
 
                                          
                                                          
  Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-alpha in normal human sera.
  
    Hansen M, Svenson M, Bendtzen K
    
    
    Clin Exp Immunol. 1992; 88(3):559-62.
  
  
    PMID: 1606741
    
          PMC: 1554525.
    
          DOI: 10.1111/j.1365-2249.1992.tb06487.x.
      
 
                                          
                                                          
  Absence of circulating interferon in patients with inflammatory bowel disease. Suggestion against an autoimmune etiology.
  
    Capobianchi M, Fais S, Di Paolo M, Agostini D, Paoluzi P, Pallone F
    
    
    Clin Exp Immunol. 1992; 90(1):85-7.
  
  
    PMID: 1382905
    
          PMC: 1554556.
    
          DOI: 10.1111/j.1365-2249.1992.tb05836.x.